- General Drug Summary
- Description
- Indomethacin is a non-steroidal antiinflammatory agent (NSAIA) with antiinflammatory, analgesic and antipyretic activity. Its pharmacological effect is thought to be mediated through inhibition of the enzyme cyclooxygenase (COX), the enzyme responsible for catalyzes the rate-limiting step in prostaglandin synthesis via the arachidonic acid pathway.
- Also Known As
- IMN; Indometacine; Indometacyna; Indomethacine; Indomethacinum; Indomethancin; Indomethazine; Indomethine; Indometicina
- Categories
- Gout Suppressants
- Structure
- Summary In Neonatal Jaundice
-
1 record(s) for Indomethacin Controvesial in Ulcerative Colitis in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 11753466
- Indomethacin
- Controvesial in Ulcerative Colitis
- Clinical Trial
- Summary
- No significant adverse effects in the treatment of Neonatal jaundice received indomethacin.
- Factors influencing successful closure with indomethacin of the patent ductus arteriosus in premature infants. Cardiovascular journal of South Africa : official , [Go to PubMed]
- The incidence of persistent patency of the ductus arteriosus (PDA) is inversely related to birth weight. A PDA contributes to pathological conditions in the neonate and timely closure in these low-L birth-L weight infants could potentially prevent these complications. Prostaglandin inhibition with indomethacin is one treatment strategy currently available. This retrospective descriptive study evaluated the parameters that influenced the effectiveness of indomethacin in closure of the PDA in 101 consecutive premature infants and the adverse effects of indomethacin in these infants. Independent variables found to increase the risk of unsuccessful closure with indomethacin significantly were caesarean section, lower haematocrit at delivery and severity of hyaline membrane disease. Non-L closure also resulted in prolonged ventilation. No significant adverse effects were recorded in the infants who received indomethacin but neonatal jaundice was more common in those infants who responded to indomethacin.
-
1 record(s) for Indomethacin NA in Neonatal Jaundice.
- PMID
- Drug Name
- Efficacy
- Evidence
- 16203599
- Indomethacin
- NA
- Review
- Summary
- With analgesic and antipyretic properties exerts its pharmacological effects by inhibiting.
- Is phototherapy a risk factor for ileus in high-risk neonates? neonatal medicine : the official journal of the E, 2005 Aug [Go to PubMed]
- Abdominal distension and bile stained aspirates are common in high-risk neonates under phototherapy (PT).
To compare the incidence of ileus and related risk factors in extremely low birth weight (ELBW) neonates who did/did not receive PT.
Retrospective detailed analysis of data on 52 consecutive ELBW neonatal admissions (1997-1999) including demographic characteristics, outcomes to discharge and common risk factors for ileus such as intrauterine growth retardation, PDA, indomethacin therapy, sepsis and enteral feeds. Ileus was defined as presence of abdominal distension and bile stained aspirate/s with/without dilated bowel loops on X-rays.
A significantly (p = 0.001) higher proportion (63.4%, 26/41) of neonates under PT developed ileus than those (1/11) who did not receive PT. The outcomes and risk factors for ileus were comparable between the two groups. Mean (+/-SD) gestational age and birth weight of those who did and did not receive PT [26 (+/-2.2) weeks and 803 (+/-133) grams vs. 27 (+/-3.2) weeks and 664 (+/-114.2) grams], and those who did and did not develop ileus [26.5 (+/-2.3) weeks and 797 (+/-102) grams vs. 28.0 (+/-1.2) weeks and 750 (+/-105) grams] were not significantly different.
Phototherapy may be an independent risk factor for ileus in ELBW neonates.